LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) – Equities researchers at HC Wainwright upped their FY2026 EPS estimates for shares of LENZ Therapeutics in a note issued to investors on Friday, October 30th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($4.18) for the year, up from their prior forecast of ($4.35). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($4.09) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q4 2026 earnings at ($0.85) EPS, FY2027 earnings at ($1.30) EPS, FY2028 earnings at ($0.90) EPS, FY2029 earnings at ($0.11) EPS and FY2030 earnings at $1.09 EPS.
A number of other research analysts also recently weighed in on LENZ. Piper Sandler decreased their price objective on shares of LENZ Therapeutics from $7.00 to $5.00 and set a “neutral” rating for the company in a research report on Monday, October 19th. Weiss Ratings lowered LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 9th. Zacks Research raised LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Finally, Citigroup reaffirmed a “buy” rating on shares of LENZ Therapeutics in a report on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $17.50.
View Our Latest Analysis on LENZ Therapeutics
LENZ Therapeutics Stock Performance
LENZ stock opened at $3.05 on Tuesday. The firm has a market cap of $95.83 million, a PE ratio of -0.68 and a beta of 0.64. The firm’s fifty day moving average is $4.04 and its 200 day moving average is $8.04. LENZ Therapeutics has a one year low of $2.80 and a one year high of $32.13.
LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.10). LENZ Therapeutics had a negative net margin of 1,134.97% and a negative return on equity of 56.10%. The firm had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $4.20 million.
Institutional Trading of LENZ Therapeutics
Several large investors have recently made changes to their positions in the company. Pinnacle Wealth Planning Services Inc. lifted its holdings in LENZ Therapeutics by 92.5% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 10,104 shares of the company’s stock valued at $39,000 after purchasing an additional 4,854 shares in the last quarter. Inscription Capital LLC acquired a new stake in LENZ Therapeutics during the 3rd quarter worth $44,000. Deutsche Bank AG acquired a new stake in LENZ Therapeutics during the 2nd quarter worth $93,000. Janney Montgomery Scott LLC purchased a new stake in shares of LENZ Therapeutics during the first quarter worth $99,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of LENZ Therapeutics during the second quarter worth $102,000. 54.32% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at LENZ Therapeutics
In other LENZ Therapeutics news, major shareholder Ra Capital Management, L.P. sold 2,718,684 shares of the stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $3.36, for a total transaction of $9,134,778.24. Following the completion of the transaction, the insider owned 57,559 shares of the company’s stock, valued at $193,398.24. This represents a 97.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.30% of the stock is owned by insiders.
Trending Headlines about LENZ Therapeutics
Here are the key news stories impacting LENZ Therapeutics this week:
- Positive Sentiment: HC Wainwright raised its earnings forecasts across 2026–2030. The analyst improved projected EPS for Q4 2026 to $(0.85), FY2026 to $(4.18), FY2027 to $(1.30), FY2028 to $(0.90), FY2029 to $(0.11), and FY2030 to $1.09. The revisions suggest a faster path toward profitability, including projected positive earnings in 2030. HC Wainwright maintained a Buy rating and a $16 price target.
- Neutral Sentiment: Analyst views remain divided. Although HC Wainwright remains bullish, it recently reduced its price target to $16, while Piper Sandler has a $5 target and a Neutral rating. The broader analyst consensus is Hold, with an average target of $17.50. LENZ Therapeutics Stock Gets Price Target Reduction from HC Wainwright
- Negative Sentiment: Major shareholder RA Capital Management sold 2.72 million shares for approximately $9.1 million. The transaction reduced RA Capital’s direct ownership by 97.93%, leaving it with only 57,559 shares. Such a large disposal can pressure the stock and may raise concerns about institutional confidence or near-term supply of shares. LENZ Therapeutics Major Shareholder Stock Sale
- Negative Sentiment: LENZ’s latest quarterly results missed expectations. The company reported a loss of $0.99 per share versus the expected loss of $0.89, while revenue of $3.38 million fell short of the $4.20 million consensus. LENZ remains unprofitable, with analysts forecasting a full-year loss of approximately $4.09 per share.
LENZ Therapeutics Company Profile
LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for the treatment of presbyopia, the age-related loss of near vision. The company is headquartered in San Diego, California, and its programs are designed to provide an alternative to reading glasses and other corrective lenses.
LENZ’s primary product candidate is aceclidine ophthalmic solution, developed under the names LNZ100 and VIZZ. The pupil-selective miotic is intended to improve near vision while preserving distance vision, without relying on the lens-shaping mechanism targeted by some other presbyopia treatments.
Read More
- Five stocks we like better than LENZ Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
